a 2022

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

PERUSINI, MA., TS. KIM, Daniela ŽÁČKOVÁ, K. PAGNANO, Jiří MAYER et. al.

Basic information

Original name

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Authors

PERUSINI, MA., TS. KIM, Daniela ŽÁČKOVÁ, K. PAGNANO, Jiří MAYER, C. PAVLOVSKY, Ivana JEŽÍŠKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, B MOIRAGHI, AI. VARELA, M. BIANCHINI, ABP. LOPES, G. DUARTE, YS. YOO, CA. SOUZA, J. MEDEIROS, HW. LEE, KH. KIM, SY. YI, MH. CHANG, S. ABELSON and DDH. KIM

Edition

64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood, 2022

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine
Změněno: 20/12/2022 15:28, Bc. Kateřina Kolesová
Displayed: 16/11/2024 03:31